United Kingdom· GB-APID-44012811000001104
Kisunla 350mg/20ml concentrate for solution for infusion vials
A donanemab product containing donanemab, registered in United Kingdom by Eli Lilly and Company Ltd. The same ATC class is registered in 11 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Donanemab is registered in 11 of 19 countries.
Countries holding a registration under ATC N06DX05 (donanemab), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 7 of them publish a price we can compare per daily dose
Donanemab · ATC N06DX05
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Donanemab
- Manufacturer
- Eli Lilly and Company Ltd
- Country
- United Kingdom (GB)
- ATC code
- N06DX05
- ATC class
- Donanemab
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin5014602102012
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Donanemab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaKISUNLAEli Lilly Nederland B.V., Utrecht
- SwitzerlandKisunla 350 mg, Konzentrat zur Herstellung einer InfusionslösungEli Lilly (Suisse) SA
- FinlandKisunlaEli Lilly Nederland B.V.
- IrelandKisunla 350 mg concentrate for solution for infusionEli Lilly Nederland B.V.
- IcelandKisunlaEli Lilly Nederland B.V.*
- Japanドナネマブ（遺伝子組換え）日本イーライリリー
- NetherlandsKisunla 350 mg concentraat voor oplossing voor infusieEli Lilly Nederland B.V.
- PolandKisunla 350 mgEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kisunla
- Liechtenstein · Kisunla
- Norway · Kisunla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f56c6657-fb98-4362-b8a0-3b11f9f5338b GET /v1/drugs/f56c6657-fb98-4362-b8a0-3b11f9f5338b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "44012811000001104",
"desc": "Kisunla 350mg/20ml concentrate for solution for infusion vials (Eli Lilly and Company Ltd)",
"form": "Solution for infusion",
"vpid": "44014311000001101",
"source": "dmd",
"vtm_id": "44014811000001105",
"strength": "17.5 mg",
"substance": "Donanemab",
"ingredient": "Donanemab",
"supplier_code": "2075101000001100"
}See everything about donanemab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.